Holen Sie sich die Stockscreener-App
50.79
1.18%
0.59
Schlusskurs vom Vortag:
$50.20
Offen:
$50.78
24-Stunden-Volumen:
3.76M
Relative Volume:
1.12
Marktkapitalisierung:
$22.51B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$1.32B
KGV:
28.52
EPS:
1.7806
Netto-Cashflow:
$897.24M
1W Leistung:
+2.67%
1M Leistung:
+6.03%
6M Leistung:
+31.72%
1J Leistung:
+53.44%
1-Tages-Spanne:
$50.50
$51.17
1-Wochen-Bereich:
$49.11
$51.65
52-Wochen-Spanne:
$32.15
$51.65
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
50.79 | 22.51B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
10% Of This Royalty Pharma Insider's Holdings Were Sold - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00 - MarketBeat
Royalty Pharma schedules two May healthcare conference webcasts - Stock Titan
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript - Insider Monkey
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised By Investing.com - Investing.com Australia
Royalty Pharma (RPRX) Margin Drop To 33.9% Tests Bullish Growth Narrative In Q1 2026 - Sahm
Improved Growth Outlook Prompts Fair Value Estimate Increase for Narrow-Moat Royalty Pharma - Morningstar
Royalty Pharma’s Earnings Call Signals Confident Growth - TipRanks
Royalty Pharma Q1 Earnings Call Highlights - MarketBeat
MSN Money - MSN
Royalty Pharma plc Q1 2026 Financial Results: Earnings, Revenue, and Risk Factors from Latest 10-Q Filing - Minichart
Royalty Pharma Q1 2026 earnings preview - MSN
Royalty Pharma plc Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth By Investing.com - Investing.com India
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript - AOL.com
Royalty Pharma Reports 10% Growth in Portfolio Receipts for Q1 2026 Driven by Strong Product Performance - Minichart
RPRX vs. AMGN: Which Stock Is the Better Value Option? - Yahoo! Finance Canada
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised - Investing.com
Royalty Pharma PLC reports results for the quarter ended March 31Earnings Summary - TradingView
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Royalty Pharma (RPRX) Valuation Check As Q1 Earnings Expectations Drive Strong Share Price Momentum - Sahm
RPRX Stock Price Prediction 2025-2026 | Royalty Pharma Plc Forecast | 24/7 Wall St. - 24/7 Wall St.
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth - Investing.com
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary - TradingView
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Royalty Pharma (NASDAQ: RPRX) grows Q1 2026 profit and cash flow - Stock Titan
Royalty Pharma plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RPRX) 2026-05-06 - Seeking Alpha
Earnings Flash (RPRX) Royalty Pharma plc Reports Q1 Revenue $631.0M - marketscreener.com
Royalty Pharma : Q1 2026 Financial Results Presentation - marketscreener.com
Royalty Pharma posts Q1 2026 Portfolio Receipts $925M; raises 2026 guidance to $3.325B‑$3.45B - TradingView
Royalty Pharma (Nasdaq: RPRX) posts strong Q1 2026 growth and raises full-year guidance - Stock Titan
Royalty Pharma PLC $RPRX Position Reduced by Swedbank AB - MarketBeat
Royalty Pharma reports first quarter 2026 results - The Manila Times
Royalty Pharma commits up to $1.25B to new deals, lifts 2026 outlook - Stock Titan
RPRX|Royalty Pharma PLC|Price:50.440|Chg%:0.24 - TradingKey
Royalty Pharma stock hits 52-week high at 50.49 USD By Investing.com - Investing.com Australia
Royalty Pharma Q1 2026 Earnings Call Transcript - MarketBeat
Royalty Pharma earnings in focus as deal activity accelerates By Investing.com - Investing.com South Africa
Royalty Pharma to Announce Q1 Earnings on May 6 - Intellectia AI
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighStill a Buy? - MarketBeat
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.48%
11.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):